Healthcare & Pharmaceutical Market Research in Ireland

BioNixus is a leading healthcare market research company in Ireland, delivering Research Ethics Committee (REC)-compliant HCP surveys, KOL mapping, and payer landscape research aligned with HPRA, NCPE, and HSE reimbursement requirements. BioNixus combines primary research depth with physician access across Ireland's leading academic medical centres and specialist hospital networks.

A healthcare market research company in Ireland designs and executes studies covering physician prescribing behaviour, HSE reimbursement and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Irish market and using it as a gateway to the wider EU.

Ireland has a single national public healthcare system administered by the HSE (Health Service Executive), rather than a provincial or state-based structure. HPRA authorisation does not guarantee market access — commercial outcomes depend on NCPE cost-effectiveness assessments, HSE reimbursement decisions under the GMS scheme, Drug Payment Scheme, and High Tech Drug Scheme, and the IPHA framework agreement, which governs industry pricing and supply arrangements with the state. Ireland is also a major global pharmaceutical manufacturing and EU headquarters hub, which shapes both stakeholder access and competitive dynamics.

BioNixus covers oncology, immunology and biologics (including biosimilar uptake policy), cardiovascular, diabetes and metabolic (including GLP-1), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Irish market.

Yes. BioNixus maintains physician and specialist networks across Ireland's leading academic medical centres and hospitals, including Trinity College Dublin, University College Dublin, RCSI, Beaumont Hospital, and St James's Hospital. For scarce specialties such as oncology or rare disease, we recruit through hospital consultant networks and rare disease specialist directories nationwide.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including HSE payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, REC review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-hospital recruitment may require extended planning timelines.

Yes. BioNixus designs and executes Irish patient research in compliance with GDPR data privacy standards, Research Ethics Committee (REC) approval processes, and HIQA oversight of health and social care standards. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling.

Yes. Irish modules can run with comparable cells across the UK, EU5 (Germany, France, Italy, Spain), the USA, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner, with Ireland often serving as the English-speaking entry point for wider EU research programmes.